Validose provides an agile dose device platform that pairs a multi-sensor Dose Exoskeleton attachment with real-time data delivery to clinicians and behavioral prompts to drive patient adherence. Its initial commercial product is an ophthalmic smart-dose eye-dropper, with a planned launch in Q2 2025. The platform is designed to support additional form factors, including a CNS-focused nasal spray device and a pill delivery system. Validose also offers a Patient Portal that sends personalized dose reminders, real-time messaging, and behavioral coaching, and a Clinician Dashboard that gives trial coordinators secure, immediate adherence insights. The company emphasizes objective, precise, and secure real-time adherence data to optimize trial outcomes and enable timely interventions. Recent financing will fund final development of the ophthalmic solution.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2025